Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAT1 genotype and methylphenidate effects on fMRI attention responses in adolescents with ADHD
ACTRN12610000652077Phase 3Completed
- Sponsor
- Dr. Tim Silk
- Start
- Sep 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of methylphenidate in attention deficit hyperactivity disorder (ADHD) (2 arms), sponsored by Dr. Tim Silk. Primary endpoints: Change in BOLD response as a function of medication and Change in BOLD response as a function of DAT1 genotype. Started Sep 2010; status: completed.
02
Drugs
methylphenidate
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on ACTRN12610000652077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12610000652077.